Secondary acute myeloid leukemia in survivors of Hodgkin lymphoma. (July 2016)

• Record Type: Journal Article
• Authors: Bhatt, Vijaya R; Giri, Smith; Verma, Vivek; Dahal, Sumit; Shah, Binay K; Pathak, Ranjan; Bociek, R Gregory; Vose, Julie M; Armitage, James O
• Is Part Of: Future oncology. Volume 12:Number 13(2016)
• Page Start: 1565
• Page End: 1575
• Publication Date: 2016-07
• Subjects: acute myeloid leukemia -- Hodgkin lymphoma -- survival; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon-2016-0048
• Languages: English
• ISSNs: 1479-6694

Abstract

Background: This large population-based study determined the epidemiology and outcomes of secondary acute myeloid leukemia (sAML) developing in Hodgkin lymphoma survivors.Methods: We utilized the Surveillance Epidemiology and End Results (SEER) 9 database to identify 104 cases of sAML.Results: Patients with sAML (median age: 47 years; 82% <60 years) were significantly younger than de novo AML cases (66 years; p < 0.01). sAML had worse overall survival (OS) than de novo AML (p < 0.01). OS was better in younger patients and in more recent years.Conclusion: Older patients with sAML have a dismal OS and should be enrolled in trials of novel therapies. Younger patients have improved OS and hence may benefit from curative intent intensive therapy and allogeneic transplant.